PA-BOOMI
6.9.2022 15:21:40 CEST | Business Wire | Press release
Boomi™, the intelligent connectivity and automation leader, today announced the appointment of former Deloitte CIO Larry Quinlan as an independent, non-executive member of its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005173/en/
Boomi Appoints Larry Quinlan to Board of Directors (Graphic: Business Wire)
“We’re thrilled to have Larry as part of our board and strategic counsel, where he will bring his proven expertise to help us navigate through our next phase as a company,” said David Meredith, CEO at Boomi. “Boomi's recent launch as a standalone organization – coupled with our category-leading technology and rapid customer growth – provides us the opportunity to continue to build an unparalleled leadership team.”
As the former Global Chief Information Officer (CIO) for Deloitte, Quinlan held responsibility for the $45B professional services firm’s technology strategy and operations, overseeing more than 10,000 information technology (IT) professionals in 175 countries. Sought-after for his understanding of strategic impacts of emerging technologies, he brings over 35 years of experience advising Fortune 500 boards and CEOs. Quinlan currently sits on numerous boards, including those of two public companies: ServiceNow (NYSE: NOW), a leader in cloud digital workflow, and Jones Lang LaSalle (NYSE: JLL), a world leader in real estate services, as well as UBS Americas Holding LLC where he chairs the Technology and Cyber Forum of the Board.
“All businesses must transform for today’s world, and intelligent connectivity and automation are crucial for success in that endeavor,” said Quinlan. “Boomi’s continued leadership, coupled with its award-winning platform and culture, make this company a force to be reckoned with. I’m honored to serve the Boomi team during this exciting time.”
Quinlan’s appointment comes after Boomi's recent independence backed by premier private equity firms, Francisco Partners and TPG, in a $4 billion transaction. As a category-leading, global software as a service (SaaS) company with the largest customer base among integration platform vendors, Boomi touts a growing user community of over 100,000 members, and one of the largest arrays of global systems integrators (GSIs) in the integration platform as a service (iPaaS) space. The company boasts a worldwide network of approximately 800 partners, including Accenture, Deloitte, SAP, and Snowflake; and partners with the largest hyperscaler cloud service providers, including Amazon Web Services, Google, and Microsoft, among others.
Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for Enterprise Integration Platform as a Service (EiPaaS) for eight consecutive years.
Recently named as one of America's fastest-growing private companies on the Inc. 5000 2022 list, Boomi also earned the Gold Globee® Award in the Platform as a Service (PaaS) category, and garnered a prestigious 5-star rating in the CRN Partner Program Guide, a definitive list of the most notable partner programs from industry-leading technology vendors that provide innovative products and flexible services through the IT channel. Additionally, Boomi celebrates numerous awards as an employer of choice, including a listing as one of Inc. Magazine’s Best Workplaces and two Comparably awards for Best CEOs for Diversity and Best Company for Career Growth. As enterprise demand for digital connectivity, integration, and intelligent automation solutions continues to grow, Boomi continues to scale rapidly and hire globally.
Additional Resources
- Learn more about the Boomi AtomSphere Platform
- Check out open roles at Boomi
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
Gartner Disclaimer:
Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, Snowflake, Amazon Web Services, Google Cloud, and Microsoft. Global organizations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2022 Boomi, LP. Boomi, the ‘B’ logo, Boomiverse, and AtomSphere are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005173/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom